SG11201809780WA - Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same - Google Patents
Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using sameInfo
- Publication number
- SG11201809780WA SG11201809780WA SG11201809780WA SG11201809780WA SG11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA SG 11201809780W A SG11201809780W A SG 11201809780WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- ebolavirus
- nucleic acid
- disclosed
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 241000711950 Filoviridae Species 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 5
- 235000017284 Pometia pinnata Nutrition 0.000 abstract 2
- 240000007653 Pometia tomentosa Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 241000766653 Macrocephalon maleo Species 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332372P | 2016-05-05 | 2016-05-05 | |
| US201662402519P | 2016-09-30 | 2016-09-30 | |
| US201762483979P | 2017-04-11 | 2017-04-11 | |
| PCT/US2017/031215 WO2017192947A1 (en) | 2016-05-05 | 2017-05-05 | Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809780WA true SG11201809780WA (en) | 2018-12-28 |
Family
ID=60203604
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809780WA SG11201809780WA (en) | 2016-05-05 | 2017-05-05 | Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same |
| SG10202011017RA SG10202011017RA (en) | 2016-05-05 | 2017-05-05 | Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011017RA SG10202011017RA (en) | 2016-05-05 | 2017-05-05 | Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11091518B2 (enExample) |
| EP (1) | EP3452068A4 (enExample) |
| JP (3) | JP7029756B2 (enExample) |
| KR (2) | KR102678400B1 (enExample) |
| CN (2) | CN110072536B (enExample) |
| AU (2) | AU2017261306B2 (enExample) |
| BR (1) | BR112018072719A2 (enExample) |
| CA (1) | CA3023098A1 (enExample) |
| MX (2) | MX2018013524A (enExample) |
| SG (2) | SG11201809780WA (enExample) |
| WO (1) | WO2017192947A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102678400B1 (ko) * | 2016-05-05 | 2024-06-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| WO2018102657A1 (en) * | 2016-12-02 | 2018-06-07 | Weiner David B | Dna antibody constructs for use against ebola virus |
| CN110655572B (zh) * | 2019-10-11 | 2022-08-16 | 中国科学院广州生物医药与健康研究院 | 一种抗丝状病毒gp蛋白的单克隆抗体及其应用 |
| WO2024233996A2 (en) * | 2023-05-11 | 2024-11-14 | The Wistar Institute Of Anatomy And Biology | Vaccines against african swine fever virus, and methods of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| KR20220012403A (ko) * | 2012-04-12 | 2022-02-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| WO2014145951A2 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of The University Of Pennsylvania | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
| SG10201806481XA (en) * | 2014-02-19 | 2018-09-27 | Emergent Biosolutions Canada Inc | Marburg monoclonal antibodies |
| AU2015311852B2 (en) * | 2014-09-03 | 2018-12-13 | Bavarian Nordic A/S | Methods and compositions for inducing protective immunity against filovirus infection |
| KR102586707B1 (ko) * | 2014-10-01 | 2023-10-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신 |
| KR102678400B1 (ko) * | 2016-05-05 | 2024-06-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
-
2017
- 2017-05-05 KR KR1020187035164A patent/KR102678400B1/ko active Active
- 2017-05-05 JP JP2019510571A patent/JP7029756B2/ja active Active
- 2017-05-05 SG SG11201809780WA patent/SG11201809780WA/en unknown
- 2017-05-05 CA CA3023098A patent/CA3023098A1/en active Pending
- 2017-05-05 SG SG10202011017RA patent/SG10202011017RA/en unknown
- 2017-05-05 EP EP17793414.8A patent/EP3452068A4/en active Pending
- 2017-05-05 CN CN201780042299.9A patent/CN110072536B/zh active Active
- 2017-05-05 WO PCT/US2017/031215 patent/WO2017192947A1/en not_active Ceased
- 2017-05-05 CN CN202410055051.8A patent/CN117887735A/zh active Pending
- 2017-05-05 BR BR112018072719-9A patent/BR112018072719A2/pt not_active Application Discontinuation
- 2017-05-05 KR KR1020247020713A patent/KR20240099514A/ko active Pending
- 2017-05-05 MX MX2018013524A patent/MX2018013524A/es unknown
- 2017-05-05 AU AU2017261306A patent/AU2017261306B2/en active Active
- 2017-05-05 US US16/098,912 patent/US11091518B2/en active Active
-
2018
- 2018-11-05 MX MX2023003934A patent/MX2023003934A/es unknown
-
2021
- 2021-08-17 US US17/404,143 patent/US12240872B2/en active Active
-
2022
- 2022-02-10 JP JP2022019743A patent/JP7584770B2/ja active Active
-
2024
- 2024-05-27 AU AU2024203524A patent/AU2024203524A1/en active Pending
- 2024-10-28 JP JP2024189281A patent/JP2025017370A/ja active Pending
-
2025
- 2025-03-03 US US19/068,349 patent/US20250257101A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117887735A (zh) | 2024-04-16 |
| AU2017261306A1 (en) | 2018-12-20 |
| SG10202011017RA (en) | 2020-12-30 |
| AU2017261306B2 (en) | 2024-02-29 |
| JP2022078067A (ja) | 2022-05-24 |
| WO2017192947A1 (en) | 2017-11-09 |
| MX2018013524A (es) | 2019-06-10 |
| EP3452068A1 (en) | 2019-03-13 |
| CA3023098A1 (en) | 2017-11-09 |
| JP7584770B2 (ja) | 2024-11-18 |
| US12240872B2 (en) | 2025-03-04 |
| JP2025017370A (ja) | 2025-02-05 |
| KR20190037200A (ko) | 2019-04-05 |
| JP2019516400A (ja) | 2019-06-20 |
| BR112018072719A2 (pt) | 2019-02-19 |
| US20190153040A1 (en) | 2019-05-23 |
| KR20240099514A (ko) | 2024-06-28 |
| US20210388033A1 (en) | 2021-12-16 |
| AU2024203524A1 (en) | 2024-06-20 |
| CN110072536A (zh) | 2019-07-30 |
| KR102678400B1 (ko) | 2024-06-26 |
| CN110072536B (zh) | 2024-02-02 |
| MX2023003934A (es) | 2023-04-26 |
| US11091518B2 (en) | 2021-08-17 |
| JP7029756B2 (ja) | 2022-03-04 |
| EP3452068A4 (en) | 2020-01-22 |
| US20250257101A1 (en) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908489XA (en) | De novo synthesized combinatorial nucleic acid libraries | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| SG11201909927RA (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
| SG11201408459VA (en) | Purification of virus like particles | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201808152PA (en) | Dna antibody constructs and method of using same | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201803593QA (en) | Engineered nucleic-acid targeting nucleic acids | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809684YA (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations |